PFE · 10-Q · 2026Q3 · Full report

Product Pipeline Progress

PFIZER INC · 2026-11-03 · Importance 41 · Surprise 42

Pfizer reported 2026 U.S. approval of Veppanu (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer and U.S. and EU approvals expanding Padcev and other products into additional treatment settings. It also reported approvals for Hympavzi in the EU and U.S., Tukysa and Talzenna in the U.S., and the 2026–2027 Comirnaty formula in the EU and U.S. Late-stage development updates included Padcev for bladder-sparing treatment and Nurtec for chronic migraine, plus candidates for pediatric pneumococcal disease and atopic dermatitis and asthma. The Phase 3 SigVie-002 study of investigational sigvotatug vedotin in previously treated advanced or metastatic non-squamous NSCLC did not meet its primary overall-survival endpoint.

Key facts

• Pfizer jointly agreed with Arvinas in May 2026 to out-license commercialization rights to vepdegestrant to Rigel Pharmaceuticals. source
• Pfizer withdrew its EMA application in September 2026 seeking an Ibrance indication extension for maintenance treatment of HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment. source
• Pfizer's Padcev with pembrolizumab was approved in the U.S. in July 2026 as neoadjuvant treatment followed by adjuvant treatment after cystectomy for adults with MIBC. source
• Pfizer's Padcev with pembrolizumab was approved in the EU in October 2026 as neoadjuvant treatment followed by adjuvant treatment after radical cystectomy for adults with resectable MIBC. source
• Pfizer voluntarily withdrew the Oxbryta NDAs on July 31, 2026, after the FDA determined there was no viable pathway to return the product to the U.S. market. source
• By November 2026, Pfizer had notified regulators outside the U.S. that it was voluntarily withdrawing Oxbryta marketing authorization. source
• Enrollment of new participants in Pfizer's osivelotor studies began in Q1 2026 after the FDA permitted study initiation and confirmed that enrollment could proceed under specified conditions. source
• Pfizer's Phase 3 SigVie-002 study of sigvotatug vedotin did not meet its primary endpoint of statistically significant overall-survival improvement versus docetaxel; the result was announced in June 2026. source